Know Cancer

or
forgot password

A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors


OBJECTIVES:

- To determine the maximum tolerated dose of methoxyamine given in conjunction with
temozolomide in patients with and without CNS disease.

- To determine the dose limiting toxicities of the combination of methoxyamine and
temozolomide in patients with and without CNS disease.

- To determine the pharmacokinetics of these two agents when given alone or in
combination, as well as the pharmacokinetic profile of methoxyamine after single
one-hour IV administration.

- To determine relative DNA damage, as single or double strand breaks by comet assay in
blood mononuclear cells which will serve as a surrogate for tumor response to the drug
combination.

OUTLINE: This is a dose escalation study of methoxyamine.

Patients receive oral temozolomide for 5 days every 28 days and methoxyamine IV over 1 hour
every 28 days. Methoxyamine IV administration will follow, within 5 minutes, initial
administration of TMZ on day 1. Courses repeat every 28 days in the absence of disease
progression or unacceptable toxicity.

Blood samples are collected periodically for correlative studies. Samples are analyzed for
methoxyamine and temozolomide pharmacokinetics, apurinic/apyrimidinic sites, and DNA strand
break determination by comet assay.


Inclusion Criteria:



- Patients must have a histologically confirmed solid tumor that is considered
incurable and is not amenable to conventional surgical, radiation therapy or
chemotherapy treatment programs.

- Prior chemotherapy and/or radiation are allowed. At least 3 weeks must have elapsed
since prior large-field radiation therapy; patients must have been off previous
anti-cancer therapy for at least 3 weeks (6 weeks for mitomycin-C and nitrosoureas);
and recovered from all treatment related toxicity. Prior temozolomide treatment is
not restricted.

- ECOG performance status (PS) 0-2 (Karnofsky PS 50-100%)

- Life expectancy ≥ 12 weeks

- Patients must have normal organ and marrow function as defined below:

- Absolute neutrophil count ≥ 1,500/μL

- Platelet count ≥ 100,000/μL

- Hemoglobin ≥ 10.0 g/dL

- Total bilirubin ≤ 1.5 mg/dL

- AST ≤ 2.5 times upper limit of normal

- Creatinine ≤ 1.5 mg/dL and/or creatinine clearance ≥ 60 mL/min

- Patients with known primary or metastatic CNS disease, are eligible for participation
in cohort B, but not in cohort A.

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients may not be receiving any other investigational agents or have received other
investigational agents for at least 3 weeks.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant and lactating women are excluded from this study because the methoxyamine
and temozolomide combination is likely to be teratogenic.

- NYHA classification III or IV heart disease

- Patients with known primary or metastatic CNS disease (cohort B) are not eligible if
they have a mini mental status exam score < 15 or evidence of leptomeningeal disease.

- Patients with pre-existing neurologic toxicity > grade1 (as per CTCAE, version 3.0)
are not eligible for participation in cohort A.

- Patients screened for participation in cohort B with pre-existing neurologic toxicity
> grade 2 (as per CTCAE, version 3.0) are not eligible, unless pre-existing
neurologic toxicity is documented in detail and patient's participation in the trial
has been approved by the neuro-oncology team at participating institutions.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum tolerated dose of methoxyamine

Outcome Time Frame:

Courses repeat every 28 days in the absence of unacceptable toxicity.

Safety Issue:

Yes

Principal Investigator

Jennifer Eads, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

CASE1Y05

NCT ID:

NCT00892385

Start Date:

August 2007

Completion Date:

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific
  • Neoplasms

Name

Location

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterCleveland, Ohio  44106-5065